Invest $50K in Johnson & Johnson to Become a Dividend Millionaire in 10 Years

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Invest $50K in Johnson & Johnson to Become a Dividend Millionaire in 10 Years

Invest $50K in Johnson & Johnson to Become a Dividend Millionaire in 10 Years

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

Warren Buffett, one of the most successful dividend investors in history, owes much of his financial success to a simple yet powerful strategy: dividend reinvestment programs (DRIP). This approach leverages the power of compounding by reinvesting dividend earnings back into the stock, creating a snowball effect that can significantly grow an investment over time.

Long-term dividend investors can take advantage of the DRIP strategy to build substantial wealth, and Johnson & Johnson (NYSE:

This is the hidden content, please

• Sign In
• or
• Sign Up

) is a prime candidate for those looking to become dividend millionaires in about ten years.

Trending: New fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends

This is the hidden content, please

• Sign In
• or
• Sign Up

Why Johnson & Johnson?

Johnson & Johnson, a global healthcare giant, has a long-standing reputation for stability, consistent dividend payments, and a robust business model. Despite challenges, such as recent legal battles and the spin-off of its consumer health division, the company ******** a solid choice for dividend investors due to its diversified revenue streams across pharmaceuticals, medical devices, and consumer health products.

The company has a history of rewarding shareholders, with a dividend yield of approximately 2.85% and a five-year dividend growth rate of 6.04%. This steady dividend growth, coupled with its resilient stock price, makes J&J an attractive option for those looking to leverage the power of compounding dividends.

Projected Growth Over 10 Years

As the table below demonstrates, an initial investment of $50,000 in Johnson & Johnson, with monthly top-ups of $500, could grow to over $1 million by 2034, assuming the stock maintains its current annual dividend growth rate of 6.04% and a projected stock price growth rate of 8% per year.

Year

Shares Owned

Starting Stock Price

Year-End Dividend After Taxes

Final Balance After Taxes

2024

261

$192.44

$1,321.90

$52,000

2025

288

$207.84

$1,568.32

$69,635

2026

318

$224.47

$1,868.83

$91,102

2027

351

$242.43

$2,230.64

$117,208

2028

387

$261.82

$2,661.54

$149,036

2029

426

$282.75

$3,170.67

$187,960

2030

469

$305.32

$3,768.40

$235,750

2031

516

$329.66

$4,466.36

$294,599

2032

566

$355.91

$5,277.32

$367,247

2033

621

$384.23

$6,215.10

$457,035

2034

681

$414.76

$7,294.72

$567,969

Don’t Miss Out: Commercial real estate has historically outperformed the stock market, but few investors have the capital or resources needed to invest in this asset class.

This is the hidden content, please

• Sign In
• or
• Sign Up

.

Recent Performance and

This is the hidden content, please

• Sign In
• or
• Sign Up

Johnson & Johnson’s stock has seen stable performance, with recent gains driven by strong earnings reports and the company’s strategic focus on high-growth areas such as oncology and immunology. The separation of its consumer health division, Kenvue, has allowed J&J to concentrate on its core businesses, potentially leading to better long-term growth prospects.

Story continues

Institutional investors are also showing confidence in Johnson & Johnson. In the first half of 2024, Vanguard increased its holdings by 2.5 million shares, while BlackRock added 1.8 million shares, signaling strong institutional support for the company’s future growth.

Analysts remain optimistic about Johnson & Johnson’s future, with several upgrading their price targets following the Kenvue spin-off. The company’s robust pipeline of new drugs, particularly in the oncology sector, is expected to drive revenue growth. Additionally, J&J’s ongoing legal resolutions are likely to remove some uncertainty, further stabilizing the stock.

Diversifying with High-Yield Alternatives

While Johnson & Johnson offers a solid path to building wealth through dividends, investors should also consider diversifying their portfolios with high-yield alternatives. Two options worth exploring are the Ascent Income Fund and the Arrived Private Credit Fund.

The

This is the hidden content, please

• Sign In
• or
• Sign Up

targets stable income from senior commercial real estate debt positions, offering a historical distribution yield of 10.38% backed by real assets. This fund provides a strong complement to dividend investing by offering payment priority and flexible liquidity options.

Similarly, the

This is the hidden content, please

• Sign In
• or
• Sign Up

simplifies investing in short-term financing for real estate projects, providing attractive yields secured by quality residential real estate. With target annualized dividends of 7-9%, this fund is an excellent way to balance risk and reward in a diversified investment strategy.

By investing in Johnson & Johnson and leveraging dividend compounding, along with exploring high-yield alternatives like the Ascent Income Fund and Arrived Private Credit Fund, investors can create a resilient, income-generating portfolio capable of weathering various market conditions. This approach can pave the way to becoming a dividend millionaire within the next decade.

This article

This is the hidden content, please

• Sign In
• or
• Sign Up

originally appeared on

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up

#Invest #50K #Johnson #Johnson #Dividend #Millionaire #Years

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up